Organization
Jiangsu Simcere Diagnostics Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd.
24 abstracts
Abstract
Impact of APC mutations on prognosis and tumor microenvironment in colorectal signet ring cell carcinoma.Org: Department of Pathology, Shanxi Cancer Hospital, Taiyuan, China, Shanxi Province Cancer Hospital, Taiyuan, Shanxi, China, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd., The State Key Laboratory of Neurology and Oncology Drug Development, Nanjing, Jiangsu, China, The Medical Department, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd.,
Abstract
Early-stage lung adenocarcinoma with a micropapillary pattern showing a distinct immunogenic tumor microenvironment.Org: Shengjing Hospital of China Medical University, The Medical Department, Jiangsu Simcere Diagnostics Co., Ltd., Jiangsu Simcere Diagnostics Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd., The State Key Laboratory of Neurology and Oncology Drug Development, Nanjing, China,
Abstract
Molecular characteristics of dedifferentiated liposarcoma with broad rhabdomyosarcomatous differentiation.Org: Sun Yat-sen University Cancer Center Gansu Hospital, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd., The State Key Laboratory of Neurology and Oncology Drug Development, Nanjing, China,
Abstract
Effect of KDR mutations on efficacy of immune checkpoint inhibitors in patients with bladder cancer.Org: Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China, Jinan, Shandong Suncadia Medicine, China National Biotec Group, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd.,
Abstract
Neoadjuvant tislelizumab combined with APF for patients with locally advanced head and neck squamous cell carcinoma: A prospective single-arm clinical trial.Org: The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital, Medical School of Nanjing University, Clinical Cancer Institute of Nanjing University, Nanjing Drum Tower Hospital, Clinical College of Nanjing Medical University,
Abstract
Identification of RPTOR mutation as a novel predictor of efficacious immunotherapy in melanoma.Org: Jiangsu Simcere Diagnostics Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd., The State Key Lab of Translational Medicine,
Abstract
Sintilimab plus gemcitabine and cisplatin as a first-line treatment for patients with advanced biliary tract cancer: A biomolecular exploratory, phase II clinical trial.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Eastern Hepatobiliary Surgery Hospital, Shanghai Eastern Hepatobiliary Surgery Hospital, the Naval Medical University, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd.,
Abstract
Correlation between MSI, TMB, and TGFBR2 gene mutation in solid tumors.Org: Qilu Hospital of Shandong University(QingDao), Jiangsu Simcere Diagnostics Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd., Nanjing Yoko Biomedical, The Affiliated Qingdao Hiser Hospital of Qingdao University, Qilu Hospital(Qingdao) Cheeloo College of Medicine, Shandong University,
Abstract
Homologous recombination-related (HRR) gene mutation profiling and the association with TMB in Chinese patients with esophageal and gastric cancer.Org: Nanjing Simcere Medical Laboratory Science Co., Ltd., Jiangsu simcere diagnostics Co,.Ltd, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd.,
Abstract
Comparison of gene alterations detected with tumor tissue and plasma in a Chinese population with advanced lung adenocarcinoma.Org: Jiangsu simcere diagnostics Co,.Ltd, The Bioinformatics Department, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd., The State Key Lab of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing, China,
Abstract
Gene expression comparison between primary aggressive luminal breast cancer and paired axillary and sentinel lymph node metastasis.Org: Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd., University of Liverpool,
Abstract
Genomic landscape of CDK6 amplification and its potential prognostic value in adult-type diffuse gliomas.Org: Department of Neurosurgery, Peking Union Medical College Hospital, Beijing, China, Nanfang Hospital, Southern Medical University, State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd.,
Abstract
Dynamic monitoring of ctDNA to predict response to immunotherapy plus chemotherapy in BTC.Org: Eastern Hepatobiliary Surgery Hospital, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd., The State Key Laboratory of Translational Medicine and Innovative Drug Development at Jiangsu Simcere Diagnostics Co. Ltd, Shanghai East Hospital, Tongji University, Shanghai, China, Tongji University School of Medicine,
Abstract
High frequency of germline mutations in DDR associated genes SLX4, MSH6, CDK4, TSC2, and BRCA2 might contribute to the occurrence of MPLC.Org: The First People's Hospital of Foshan, Foshan First People's Hospital, China National Biotec Group, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd., The State Key Laboratory of Translational Medicine and Innovative Drug Development at Jiangsu Simcere Diagnostics Co. Ltd,
Abstract
Tumor immune microenvironment of different lesions in patients with multiple primary lung cancer.Org: Jiangsu Simcere Diagnostics Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd., The State Key Lab of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing, China,
Abstract
Correlation of low B7-H6 expression with efficacy of immunotherapy inpatients with melanoma.Org: Jiangsu Simcere Diagnostics Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd., The State Key Lab of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing, China,
Abstract
Homologous recombination-related (HRR) gene mutations in patients with glioma and their relevance to genomic characteristics, tumor mutation burden (TMB), and prognosis.Org: Jinan, China, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd., The State Key Lab of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing, China,
Abstract
Clinical and genomic characteristics between DDR germline and somatic mutations in pan-cancer.Org: Jiangsu Simcere Diagnostics Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd., The State Key Lab of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing, China,
Abstract
Homologous recombination-related (HRR) gene mutation profiling and the association with TMB in Chinese patients with urological cancer.Org: Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Jiangsu Institute of Cancer Research, Affiliated Cancer Hospital of Nanjing Medical University, Nanjing Simcere Medical Laboratory Science Co., Ltd., Jiangsu simcere diagnostics Co,.Ltd,
Abstract
Molecular characteristics of KRAS mutations in Chinese patients with cancer.Org: General Hospital of Ningxia Medical University, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd., The State Key Lab of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing, China,
Abstract
Homologous recombination-related (HRR) gene mutation profiling and the association with TMB in Chinese patients with pancreatic cancer.Org: Nanjing Simcere Medical Laboratory Science Co., Ltd., Jiangsu simcere diagnostics Co,.Ltd, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd.,
Abstract
Clinical and molecular Characterization of NSCLCs with MET exon 14 skipping mutation coexist MET amplification.Org: Jilin University, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd., The State Key Lab of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing, China,
Abstract
Serial ctDNA monitoring to predict response in mCRC patients treated with anlotinib in combination with oxaliplatin and capecitabine (CAPEOX) as the first-line therapy.Org: Cancer Center Zhejiang University, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd., State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd,
Abstract
Tumor immune microenvironment (TIME) analysis of stage I lung adenocarcinoma with micropapillary pattern.Org: Shengjing Hospital of China Medical University, The Medical Department, Jiangsu Simcere Diagnostics Co., Ltd., Jiangsu Simcere Diagnostics Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd., The State Key Lab of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing, China,